538965 Stock Overview
Engages in the manufacture and sale of pharmaceutical formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Concord Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹37.59 |
| 52 Week High | ₹61.50 |
| 52 Week Low | ₹30.59 |
| Beta | 0.46 |
| 1 Month Change | 4.42% |
| 3 Month Change | 1.10% |
| 1 Year Change | -13.05% |
| 3 Year Change | 21.45% |
| 5 Year Change | 151.44% |
| Change since IPO | 88.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 538965 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.3% | 1.3% | -3.2% |
| 1Y | -13.0% | 39.0% | 18.7% |
Return vs Industry: 538965 underperformed the Indian Pharmaceuticals industry which returned 39% over the past year.
Return vs Market: 538965 underperformed the Indian Market which returned 18.7% over the past year.
Price Volatility
| 538965 volatility | |
|---|---|
| 538965 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 538965 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 538965's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 185 | Seelam Reddy | concorddrugs.in |
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products. The company also provides ready-to-fill pellets and multiple unit pellets system; drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers.
Concord Drugs Limited Fundamentals Summary
| 538965 fundamental statistics | |
|---|---|
| Market cap | ₹375.90m |
| Earnings (TTM) | -₹5.09m |
| Revenue (TTM) | ₹524.80m |
0.7x
P/S Ratio-73.8x
P/E RatioIs 538965 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 538965 income statement (TTM) | |
|---|---|
| Revenue | ₹524.80m |
| Cost of Revenue | ₹430.28m |
| Gross Profit | ₹94.51m |
| Other Expenses | ₹99.61m |
| Earnings | -₹5.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 18.01% |
| Net Profit Margin | -0.97% |
| Debt/Equity Ratio | 56.3% |
How did 538965 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 01:30 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Concord Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|